🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Can a new protein bring RNA drugs where they can't reach? J&J vet Sue Dillon's Ionis-partnered biotech gets $88M to prove yes - endpts.com/can-a-new-prot…

Check out our feature in today's Philadelphia Inquirer inquirer.com/business/gene-…

Welcome Aro Biotherapeutics to the Northpond Ventures family! Looking forward to working with Sue Dillon and the team to make #centyrin technology a reality for #RNA therapeutics! @Cowen_Inc HealthCap #BVFPartners #RidgebackCapital Johnson & Johnson Innovation BioMotiv Ionis arobiotx.com/aro-88-million

Big news from uCity-based and @BioLabsPhilly member, Aro Biotherapeutics! inquirer.com/business/gene-…

Another University City company making waves in the biotech realm! Congratulations to Aro Biotherapeutics, based out of @CICPhilly, for raising $88 million toward bringing its line of RNA-based drugs to market: inquirer.com/business/gene-…

.Aro Biotherapeutics is working to deliver transformative genetic medicines to patients that desperately need them. We’re proud to support your efforts alongside @Cowen_Inc and many other impactful investors. Congratulations on your Series A! #biotech fusion.inquirer.com/business/gene-…

We've spotted leadership and funding news in the first few days of the new year for Ben Franklin TELA Bio Aro Biotherapeutics + @CarismaTherape1 bit.ly/3hN5Suc

Find our article in Endpoints featuring Aro's Co-Founders Sue Dillon and Karyn O'Neil: endpts.com/can-a-new-prot…

A $1.4B bio-$ deal w/Ionis sparked Aro Biotherapeutics's $88M series A. BioCentury's mysterious Karen T. chats w/ CEO & $JNJ vet Sue Dillon on why Aro backburned cancer for orphan muscle disease & an autoimmune disorder, growing her team & what's next biocentury.com/article/633238

Have you seen our newly redesigned website? You can check out open positions at arobiotx.com/careers

Aro is excited to welcome Adam Dinerman and Zhonghao Liu to our leadership team! businesswire.com/news/home/2021…

We are very excited to announce the expansion of both our team and our space! arobiotx.com/aro-new-headqu…

Join us TODAY at 2pm at TIDES USA 2022 in Boston as our Co-founder & CSO, Karyn ONeil, gives her talk on exciting progress of our lead program. Make sure to reach out if you there! #Aro #PompeDisease #RareDisease #oligonucleotides #Centyrin arobiotx.com/aro-treatment-…

We are excited to announce that the FDA recently has granted Orphan Drug Designation for ABX1100, our lead program in Pompe disease #Aro #PompeDisease #RareDisease #oligonucleotides #Centyrin #Pompe lnkd.in/ewTTcJP5

We are excited to announce that the FDA has granted Rare Pediatric Drug Designation for ABX1100, our lead program in Pompe Disease! businesswire.com/news/home/2022…

Panelists include Tom Barnes, PhD, CEO, @Orna_TX; Susan Dillon, PhD, President & CEO, Aro Biotherapeutics; David Lockhart, PhD, President & CSO, ReCode Therapeutics; & Brian McVeigh, Chairman, CEO, & Co-Founder, Code Biotherapeutics. #ChardanGMConf #CGMC2022 #GeneticMedicines

We are honored to have Oligonucleotide Therapeutics Society highlight our company, leaders and lead program, ABX1100, for the potential treatment of Pompe Disease! #ots #oligonucleotide #Aro #geneticdiseases #pompe #sirna #centyrins oligotherapeutics.org/centyrins-effe…

We are honored to have Sue Dillon, our Co-Founder and CEO, recognized as one of the top 20 women blazing trails in biopharma R&D endpts.com/special-report…